Literature DB >> 16952072

Drug evaluation: AP-23573--an mTOR inhibitor for the treatment of cancer.

Laurie Elit1.   

Abstract

ARIAD Pharmaceuticals Inc is developing intravenous and oral formulations of AP-23573, a rapamycin analog and inhibitor of mTOR (mammalian target of rapamycin) that blocks the proliferation and migration of vascular smooth muscle cells, for the potential treatment of cancer, including solid and hematological forms.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16952072

Source DB:  PubMed          Journal:  IDrugs        ISSN： 1369-7056


  4 in total

1.  A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.

Authors:  José Baselga; Serafin M Morales; Ahmad Awada; Joanne L Blum; Antoinette R Tan; Marianne Ewertz; Javier Cortes; Beverly Moy; Kathryn J Ruddy; Tufia Haddad; Eva M Ciruelos; Peter Vuylsteke; Scot Ebbinghaus; Ellie Im; Lamar Eaton; Kumudu Pathiraja; Christine Gause; David Mauro; Mary Beth Jones; Hope S Rugo
Journal:  Breast Cancer Res Treat       Date:  2017-03-21       Impact factor: 4.872

2.  A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.

Authors:  Hope S Rugo; Olivier Trédan; Jungsil Ro; Serafin M Morales; Mario Campone; Antonino Musolino; Noémia Afonso; Marta Ferreira; Kyong Hwa Park; Javier Cortes; Antoinette R Tan; Joanne L Blum; Lamar Eaton; Christine K Gause; Zhen Wang; Ellie Im; David J Mauro; Mary Beth Jones; Andrew Denker; José Baselga
Journal:  Breast Cancer Res Treat       Date:  2017-07-05       Impact factor: 4.872

3.  Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours.

Authors:  S A Piha-Paul; P N Munster; A Hollebecque; G Argilés; O Dajani; J D Cheng; R Wang; A Swift; A Tosolini; S Gupta
Journal:  Eur J Cancer       Date:  2015-07-18       Impact factor: 9.162

Review 4.  Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.

Authors:  William H Chappell; Linda S Steelman; Jacquelyn M Long; Ruth C Kempf; Stephen L Abrams; Richard A Franklin; Jörg Bäsecke; Franca Stivala; Marco Donia; Paolo Fagone; Graziella Malaponte; Maria C Mazzarino; Ferdinando Nicoletti; Massimo Libra; Danijela Maksimovic-Ivanic; Sanja Mijatovic; Giuseppe Montalto; Melchiorre Cervello; Piotr Laidler; Michele Milella; Agostino Tafuri; Antonio Bonati; Camilla Evangelisti; Lucio Cocco; Alberto M Martelli; James A McCubrey
Journal:  Oncotarget       Date:  2011-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.